Trial of 2009 Influenza A (H1N1) Monovalent MF59-Adjuvanted Vaccine

Tristan Clark, Manish Pareek, Katja Höschler, +4

New England Journal of Medicine

Development and validation of the short version of the Psychological General Well-Being Index (PGWB-S)

Enzo Grossi, Nicola Groth, Paola Mosconi, +4

Health and Quality of Life Outcomes

Enhanced Immunogenicity of Seasonal Influenza Vaccines in Young Children Using MF59 Adjuvant

Timo Vesikari, Michele Pellegrini, Aino Karvonen, +4

The Pediatric Infectious Disease Journal

MF59-adjuvanted versus non-adjuvanted influenza vaccines: Integrated analysis from a large safety database

Michele Pellegrini, Uwe Nicolay, Kelly Lindert, +2

Vaccine

VaccinationVaccine SafetyCross-protectionImmunologyVaccine Efficacy +8

Effectiveness of Adjuvanted Influenza Vaccination in Elderly Subjects in Northern Italy

S. Mannino, Marco Villa, Giovanni Apolone, +8

American Journal of Epidemiology

Elderly SubjectsNorthern ItalyTrivalent Inactivated VaccineFlu VaccinationVaccine Hesitancy +15

Clinical Efficacy of Cell Culture–Derived and Egg‐Derived Inactivated Subunit Influenza Vaccines in Healthy Adults

Sharon E. Frey, Timo Vesikari, Agnieszka Szymczakiewicz‐Multanowska, +4

Clinical Infectious Diseases

MF59®-adjuvanted influenza vaccine (FLUAD®) in children: Safety and immunogenicity following a second year seasonal vaccination

Timo Vesikari, Nicola Groth, Aino Karvonen, +2

Vaccine

VaccinologyVaccine SafetyCross-protectionVaccinationVaccine Development +7

Safety and Immunogenicity of a Novel Influenza Subunit Vaccine Produced in Mammalian Cell Culture

Agnieszka Szymczakiewicz‐Multanowska, Nicola Groth, Roberto Bugarini, +5

The Journal of Infectious Diseases

Trial of Influenza A (H1N1) 2009 Monovalent MF59-Adjuvanted Vaccine — Preliminary Report

Tristan Clark, Manish Pareek, Katja Höschler, +5

ImmunodeficienciesImmunologyImmunodominanceImmunotherapeuticsFlu Vaccination +18

Dose ranging of adjuvant and antigen in a cell culture H5N1 influenza vaccine: Safety and immunogenicity of a phase 1/2 clinical trial

Wendy A. Keitel, Nicola Groth, Maria Lattanzi, +4

Vaccine

VaccinationPhase 1/2Cross-protectionVaccine DevelopmentImmunology +8